Over 4,000 people downloaded Courage Against Cancer’s free guides last month. Now, one small $5 donation can help bring life-saving treatments closer to FDA approval — so one day, no child or family will be denied care because of cost.
Over 4,000 people downloaded Courage Against Cancer’s free guides last month. Now, one small $5 donation can help bring life-saving treatments closer to FDA approval — so one day, no child or family will be denied care because of cost.
The future of cancer treatment lies in combination. Discover the compelling science suggesting how repurposed drugs like ivermectin and mebendazole could work synergistically with standard therapies to improve outcomes and overcome treatment resistance.
G’day mates — it’s me, Coco the Koala, and I can hardly contain my excitement! Today’s a historic moment for our Courage Against Cancer family. 🧬
We’ve just submitted our very first Sponsored Research Agreement (SRA) to MD Anderson Cancer Center — one of the world’s leading institutions in cancer research. Together, we’re launching a preclinical trial studying ivermectin and mebendazole as potential treatments against ovarian cancer.
It’s the first courageous step toward FDA-approved, non-chemotherapy cancer therapies — and I’m beaming with hope! Stay tuned as we climb this new branch of discovery, one brave leaf at a time.
Stay Courageous, mates. Healing is possible.
— Coco the Koala 🐨
Preclinical trials serve as a critical stepping stone in the journey from laboratory discovery to human application, especially in the realm of non-conventional cancer therapies. This article examines the significance of preclinical trials in the therapeutic development of promising drugs like Ivermectin and Mebendazole. By highlighting their current research landscape, we emphasize the undeniable importance of this phase in paving the way for groundbreaking cancer treatments.
Facing limited options? This guide helps patients and caregivers navigate the difficult path of considering repurposed drugs, emphasizing safety, open communication with your oncologist, and informed decision-making.
Repurposing existing drugs like ivermectin and mebendazole offers a groundbreaking path forward in the war against cancer. Learn how Courage Against Cancer’s preclinical work on ovarian cancer may help establish the safety, mechanisms, and efficacy of these overlooked therapies — and how you can help us bridge science and compassion in the fight for human healing.
Courage Against Cancer explores how ivermectin and mebendazole — two promising repurposed drugs — may enhance the effectiveness of standard cancer treatments. Learn how our ovarian cancer preclinical study aims to uncover synergistic potential that could redefine the future of integrative oncology.
In the face of a growing cancer crisis, the urgent need for alternative treatment options has become increasingly clear. This article examines the limitations of conventional therapies like chemotherapy and radiation and why embracing non-traditional treatments, such as those involving Ivermectin and Mebendazole, is crucial for enhancing patient outcomes and quality of life. By diversifying treatment options, we can provide hope to patients and families during their most challenging times.
In a landscape dominated by hype and headlines, our foundation is dedicated to a single, clear mission: moving the conversation about repurposed drugs like ivermectin and mebendazole from anecdote to evidence through rigorous, independent science.
Courage Against Cancer announces a new preclinical research initiative studying ivermectin and mebendazole against ovarian cancer. Learn what science currently shows about these repurposed antiparasitic drugs — and why this research may change the future of cancer therapy.